Boston Scientific Corporation $BSX Shares Sold by Tandem Capital Management Corp ADV

Tandem Capital Management Corp ADV trimmed its stake in Boston Scientific Corporation (NYSE:BSX) by 1.2% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53,044 shares of the medical equipment provider’s stock after selling 660 shares during the period. Boston Scientific comprises approximately 2.9% of Tandem Capital Management Corp ADV’s investment portfolio, making the stock its 7th biggest position. Tandem Capital Management Corp ADV’s holdings in Boston Scientific were worth $5,697,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Sound Income Strategies LLC increased its holdings in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 120 shares during the period. 1248 Management LLC acquired a new stake in Boston Scientific in the first quarter valued at $26,000. Y.D. More Investments Ltd acquired a new stake in Boston Scientific in the first quarter valued at $27,000. Oliver Lagore Vanvalin Investment Group acquired a new stake in Boston Scientific in the second quarter valued at $37,000. Finally, Activest Wealth Management grew its holdings in Boston Scientific by 6,216.7% during the 1st quarter. Activest Wealth Management now owns 379 shares of the medical equipment provider’s stock worth $38,000 after acquiring an additional 373 shares during the period. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $5,231,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at approximately $18,659,923.46. The trade was a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $17,972,457 in the last quarter. 0.50% of the stock is owned by insiders.

Boston Scientific Price Performance

BSX stock opened at $96.73 on Thursday. The stock has a market capitalization of $143.33 billion, a PE ratio of 57.58, a price-to-earnings-growth ratio of 2.31 and a beta of 0.61. The company’s 50-day moving average is $102.34 and its 200-day moving average is $101.96. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter last year, the firm earned $0.62 EPS. The firm’s revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Royal Bank Of Canada reiterated an “outperform” rating and set a $125.00 price target on shares of Boston Scientific in a report on Monday, September 29th. Needham & Company LLC reiterated a “buy” rating and set a $121.00 price target on shares of Boston Scientific in a report on Wednesday, October 1st. Robert W. Baird increased their price target on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Leerink Partnrs upgraded Boston Scientific to a “strong-buy” rating in a report on Monday, June 16th. Finally, Canaccord Genuity Group increased their price target on Boston Scientific from $131.00 to $132.00 and gave the stock a “buy” rating in a report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Boston Scientific has an average rating of “Buy” and an average price target of $120.71.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.